Progression-free survival and overall survival. Progression-free... | Download Scientific Diagram
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic
Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy | BMC Cancer | Full
Cancers | Free Full-Text | Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
Definition of progression free survival and overall survival for the... | Download Scientific Diagram
The Arts, Sciences and Medicine: Progression Free Survival (PFS)
Extrapolation from Progression Free Survival to Overall Survival in Oncology | PPT
Comparison of progression-free survival (A) or overall survival (B)... | Download Scientific Diagram
Progression-free survival and overall survival curves for all patients... | Download Scientific Diagram
Disease-Free Survival As a Clinical Trial Endpoint: Does It Matter, and to Whom?
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450) - ScienceDirect
Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials - ScienceDirect
Estimating progression-free survival in patients with glioblastoma using routinely collected data | Journal of Neuro-Oncology
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study | Leukemia
Extrapolation from Progression Free Survival to Overall Survival in Oncology | PPT
Cancers | Free Full-Text | Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
Historical time to disease progression and progression‐free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early‐phase trials - London - 2017 - Cancer - Wiley
Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
Understanding Overall Survival in Metastatic Breast Cancer